Ubiquitin-conjugating enzyme E2 Q2 (UBE2Q2)

Ubiquitin-conjugating enzyme E2 Q2 (UBE2Q2) is a member of the E2 family of enzymes, which play a central role in the ubiquitin-proteasome system, responsible for post-translational modification of target proteins by attaching ubiquitin. UBE2Q2 is characterized by an extended N-terminus distinct from canonical E2s and interacts with multiple E3 ubiquitin ligases, contributing to substrate specificity in cellular ubiquitylation events. Through these activities, UBE2Q2 regulates essential cellular processes including protein turnover, cell cycle progression, and cellular stress response. Aberrant expression of UBE2Q2 has been linked to cancer, particularly in tumor progression and prognosis for certain carcinomas. Despite its role as a potential therapeutic target, there are currently no known selective small-molecule inhibitors in clinical or late preclinical development.

Other names

UBE2Q2E2Q2HsUbcQ2

No specific small-molecule mechanism is established for selective UBE2Q2 modulation. Mechanistically, any targeted E2 inhibitor would likely function by blocking E2’s interaction with E1 (ubiquitin-activating) or E3 (ubiquitin-ligase) enzymes, or by interfering with the active-site cysteine crucial for thioester bond formation. For E2 enzymes in general, small-molecule inhibition is hypothesized to prevent ubiquitin transfer to substrate proteins.